Co-Diagnostics financials
$1.07−3.60%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $622.5K | $3.9M | $6.8M | $34.2M | $97.9M | $74.6M | $215.0K | $39.9K | $7.7K |
| Gross profit | $400.1K | $2.9M | $2.6M | $28.7M | $86.3M | $58.0M | $102.5K | $30.5K | $7.4K |
| Gross margin | 64.3% | 74.5% | 38.6% | 84.0% | 88.2% | 77.7% | 47.7% | 76.5% | 96.1% |
| Operating income | -$50.2M | -$40.1M | -$42.7M | -$27.0M | $46.1M | $41.7M | -$5.9M | -$6.1M | -$4.6M |
| Net income | -$46.9M | -$37.6M | -$35.3M | -$14.2M | $36.7M | $42.5M | -$6.2M | -$6.3M | -$7.0M |
| Net margin | −7533.6% | −961.4% | −518.7% | −41.6% | 37.5% | 57.0% | −2882.0% | −15714.3% | −90827.9% |
| Diluted EPS | $-35.25 | $-37.22 | $-36.00 | $-13.50 | $36.90 | $45.60 | $-11.10 | $-15.00 | $-18.90 |
| EBITDA | -$30.2M | -$38.7M | -$41.5M | -$10.3M | $46.4M | $41.8M | -$5.8M | -$6.1M | -$4.5M |
| Operating cash flow | -$29.1M | -$29.2M | -$22.1M | $6.6M | $41.1M | $28.2M | -$5.5M | -$4.1M | -$3.2M |
| Free cash flow | -$29.8M | -$29.9M | -$23.4M | $5.1M | $40.4M | $27.4M | -$5.6M | -$4.1M | -$3.3M |
| Diluted shares | 1.3M | 1.0M | 1.0M | 1.0M | 1.0M | 0.9M | 0.6M | 0.4M | 0.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $11.9M | $2.9M | $14.9M | $23.0M | $88.6M | $43.0M |
| Short-term investments | $0.00 | $26.8M | $43.6M | $58.3M | $1.3M | $4.3M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $24.7M | $63.6M | $95.3M | $123.1M | $160.0M | $71.2M |
| Total liabilities | $4.1M | $9.7M | $9.3M | $8.6M | $25.6M | $4.5M |
| Shareholders' equity | $20.6M | $53.9M | $86.0M | $114.5M | $134.5M | $66.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology